Plasma ACE2 and risk of death or cardiometabolic diseases

Large epidemiological study of association of plasma ACE2 levels with CVD risk

Cardiovascular diseases have been one of the most studied comorbidities in connection with COVID-19. A study by researchers at Hamilton Health Sciences in Ontario, Canada has examined the levels of the SARS-CoV-2 virus cellular receptor, ACE2, in more than 10,000 subjects from a highly diverse cohort from 5 continents. The Olink assay for ACE2 was used to measure this protein, and the authors found clear associations between plasma levels and the risk of major cardiovascular events, such as heart failure, stroke, and myocardial infarction.

The study was recently published in The Lancet:

Narula et. al. (2020) Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. The Lancet, DOI: 10.1016/S0140-6736(20)31964-4 – see the article here.

Get the full story on Olink and the COVID-19 pandemic